Eatontown, NJ, October, 19 2016. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Tranexamic Acid Injection, 1,000mg/10mL strength. This launch adds to Avet’s growing portfolio of generic injectable products. Tranexamic Acid is the AP rated generic equivalent to the antifibrinolytic drug Cyklokapron®. It is indicated for short-term use to reduce or prevent hemorrhaging for patients with hemophilia. According to IMS data for the twelve-months ended August 2016, the U.S. market for Tranexamic Acid injection approximated $58.1 million.